On May 13, 2019, Milestone Pharmaceuticals Inc. announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.
Milestone Pharmaceuticals Inc., a Montreal-based company, is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications.
Osler, Hoskin & Harcourt LLP advised Milestone Pharmaceuticals Inc. with a team led by Nathalie Beauregard (Corporate) and consisting of Jeremy Brisset, Fancois Paradis, and Daniel Stysis (Corporate).